SMS Pharmaceuticals
Ticker > Company >

SMS Pharmaceuticals share price

SMS Pharmaceuticals Ltd.

NSE: SMSPHARMA BSE: 532815 SECTOR: Pharmaceuticals & Drugs  48.88 K   73   10

237.90
+0.95 (0.40%)
BSE: 01 Sep 04:01 PM

Price Summary

Today's High

₹ 241

Today's Low

₹ 231.1

52 Week High

₹ 398

52 Week Low

₹ 175

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 2109.03 Cr.

Enterprise Value

₹ 2353.01 Cr.

No. of Shares

8.87 Cr.

P/E

30.02

P/B

3.05

Face Value

₹ 1

Div. Yield

0.17 %

Book Value (TTM)

₹  77.98

CASH

₹ 36.2 Cr.

DEBT

₹ 280.18 Cr.

Promoter Holding

66.26 %

EPS (TTM)

₹  7.93

Sales Growth

35.86%

ROE

9.53 %

ROCE

11.25%

Profit Growth

1110.03 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year35.86%
3 Year7.99%
5 Year8.81%

Profit Growth

1 Year1110.03%
3 Year-6.76%
5 Year3.58%

ROE%

1 Year9.53%
3 Year8.37%
5 Year9.94%

ROCE %

1 Year11.25%
3 Year9.06%
5 Year11.36%

Debt/Equity

0.517

Price to Cash Flow

42.08

Interest Cover Ratio

3.8112

CFO/PAT (5 Yr. Avg.)

1.15149041050822

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 66.26 32.49
Mar 2025 66.26 37.60
Dec 2024 64.67 19.40
Sep 2024 64.67 19.40
Jun 2024 64.67 19.40
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company’s PEG ratio is 0.0270409476591426.
  • The company has a good cash flow management; CFO/PAT stands at 1.15149041050822.

 Limitations

  • The company has shown a poor profit growth of -6.75561471401885% for the Past 3 years.
  • The company has shown a poor revenue growth of 7.99088098079244% for the Past 3 years.
  • Promoter pledging is high as 32.49%.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 164.45 196.75 173.35 248.2 196.05
Total Expenditure 130.99 164.89 140.05 206.85 157.19
Operating Profit 33.47 31.86 33.3 41.35 38.86
Other Income 1.37 1.31 2.13 1.42 0.59
Interest 4.67 4.61 4.2 5.07 5.84
Depreciation 8.38 8.62 8.7 8.64 9.75
Exceptional Items 0 0 0 0 0
Profit Before Tax 21.78 19.94 22.53 29.07 23.86
Tax 5.46 5.68 5.36 8.44 5.65
Profit After Tax 16.33 14.26 17.17 20.62 18.21
Adjusted EPS (Rs) 1.93 1.68 2.03 2.33 2.05

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 411.95 563.18 519.87 522.05 709.26
Total Expenditure 331.92 442.04 405.1 467.32 592.28
Operating Profit 80.02 121.14 114.77 54.74 116.98
Other Income 5.11 3.45 5.2 4.91 4.46
Interest 12.32 11.19 19.16 21.97 23.6
Depreciation 22.07 22.28 32.15 32.13 31.52
Exceptional Items 0 0 0 0 0
Profit Before Tax 50.76 91.12 68.65 5.55 66.33
Tax 18.07 30.16 0.62 1.47 16.91
Net Profit 32.69 60.96 68.04 4.08 49.42
Adjusted EPS (Rs.) 3.86 7.2 8.04 0.48 5.84

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 8.47 8.47 8.47 8.47 8.47
Total Reserves 358.96 419.76 485.3 486.63 562.02
Borrowings 68.22 147.41 149.5 121.13 122.09
Other N/C liabilities 46.25 58.85 43.23 43.04 43.96
Current liabilities 154.21 211.43 211.48 254.97 346.72
Total Liabilities 636.1 845.91 897.97 914.24 1083.25
Assets
Net Block 280.49 457.36 437.99 412.02 437.26
Capital WIP 42.12 6.74 11 33.19 30.27
Intangible WIP 0 0 0 0 0
Investments 45 45 45 45.1 45.1
Loans & Advances 38.47 9.1 9.32 10.7 19.04
Other N/C Assets 2.25 2.38 2.61 2.54 2.69
Current Assets 227.78 325.33 392.05 410.7 548.89
Total Assets 636.1 845.91 897.97 914.24 1083.25
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 50.76 91.12 68.65 5.55 66.33
Adjustment 28.66 27.76 49.7 52.79 53.74
Changes in Assets & Liabilities -27.6 -12.38 -58.38 -31.29 -54.55
Tax Paid -12.1 -16.05 -14.92 -4.6 -15.4
Operating Cash Flow 39.71 90.45 45.06 22.45 50.12
Investing Cash Flow -42.56 -151.59 -27.15 -29.76 -52.07
Financing Cash Flow -2.4 92.02 -11.75 -31.97 30.68
Net Cash Flow -5.25 30.88 6.16 -39.28 28.73

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 64.67 64.67 64.67 66.26 66.26
hima bindu potluri 17.73 17.73 17.73 16.93 16.93
potluri infra projects ll... 8.68 8.68 8.68 9.98 9.98
potluri laboratories priv... 1.32 1.32 1.32 1.26 1.26
ramesh babu potluri 18.49 18.49 18.49 20.48 20.48
trilok potluri 2.58 2.58 2.58 2.47 2.47
tvt infracon llp 0.12 0.12 0.12 0.11 0.11
vamsi krishna potluri 15.74 15.74 15.74 15.03 15.03
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 35.33 35.33 35.33 33.74 33.74
aniruddh mundra 1.13 1.13 1.13 1.08 1.08
investor education and pr... 0.08 0.08 0.08 - 0.08
sudeepthi gopineedi 1.56 1.56 1.56 1.49 1.49
venkata praveen talluri 1.56 1.56 1.56 1.49 1.49
venkata subbaraju penmats... - - 2.13 2.03 2.03
vivek mundra 1.23 1.23 1.23 1.18 1.18
investor education and pr... - - - 0.08 -
quant mutual fund - quant... - 2.54 2.54 2.43 -
venkata subbaraju penmats... 2.13 2.13 - - -
quant mutual fund - quant... 2.13 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CARE
Credit CARE
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY23
Concall Q3FY24
Concall Q2FY24
Concall Q2FY22
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY23
Presentation Q4FY22
Presentation Q3FY24
Presentation Q2FY22

Company News

SMS Pharmaceuticals gets EIR for Central Laboratory Analytical Services 28 Aug, 12:50 PM SMS Pharmaceuticals informs about disclosure 25 Aug, 3:52 PM SMS Pharmaceuticals informs about updates 22 Aug, 2:06 PM SMS Pharmaceuticals informs about disclosure 22 Aug, 10:38 AM SMS Pharmaceuticals - Quaterly Results 9 Aug, 1:32 PM SMS Pharmaceuticals - Quaterly Results 9 Aug, 1:32 PM SMS Pharmaceuticals - Quaterly Results 9 Aug, 1:32 PM SMS Pharmaceuticals informs about press release 10 Jul, 3:22 PM SMS Pharmaceuticals informs about disclosure 3 Jul, 9:42 AM SMS Pharmaceuticals informs about outcome of board meeting 1 Jul, 6:08 PM SMS Pharmaceuticals informs about disclosure 1 Jul, 2:45 PM SMS Pharmaceuticals informs about disclosure 1 Jul, 2:42 PM USFDA concludes inspection at SMS Pharmaceuticals’ Central Laboratory Analytical Services 25 Jun, 6:36 PM SMS Pharmaceuticals informs about newspaper advertisements 2 Jun, 12:55 PM SMS Pharmaceuticals - Quaterly Results 30 May, 6:06 PM SMS Pharmaceuticals - Quaterly Results 30 May, 6:06 PM SMS Pharmaceuticals informs about press release 2 May, 5:35 PM SMS Pharmaceuticals informs about disclosure 1 Apr, 12:59 PM SMS Pharmaceuticals informs about disclosure 1 Apr, 10:17 AM SMS Pharmaceuticals informs about closure of trading window 31 Mar, 4:51 PM SMS Pharmaceuticals informs about disclosure 29 Mar, 12:05 PM SMS Pharmaceuticals informs about disclosure 29 Mar, 12:02 PM SMS Pharmaceuticals informs about disclosure 29 Mar, 12:00 PM SMS Pharmaceuticals informs about disclosure 29 Mar, 11:59 AM SMS Pharmaceuticals completes USFDA inspection at Hyderabad facility 22 Mar, 11:54 AM SMS Pharmaceuticals informs about updates 22 Mar, 11:06 AM SMS Pharmaceuticals - Quaterly Results 12 Feb, 2:21 PM SMS Pharmaceuticals - Quaterly Results 12 Feb, 2:21 PM SMS Pharmaceuticals - Quaterly Results 12 Feb, 2:21 PM Sms Pharmaceuticals informs about trading window closure 28 Dec, 12:22 PM SMS Pharmaceuticals - Quaterly Results 8 Nov, 6:57 PM SMS Pharmaceuticals - Quaterly Results 8 Nov, 6:57 PM SMS Pharmaceuticals informs about communication to shareholders 29 Aug, 4:27 PM SMS Pharmaceuticals - Quaterly Results 5 Aug, 3:23 PM SMS Pharmaceuticals - Quaterly Results 5 Aug, 3:23 PM SMS Pharmaceuticals - Quaterly Results 5 Aug, 3:23 PM SMS Pharmaceuticals informs about certificate 12 Jul, 10:14 AM SMS Pharmaceuticals - Quaterly Results 29 May, 1:33 PM SMS Pharmaceuticals informs about disclosures 21 Mar, 2:44 PM SMS Pharmaceuticals informs about disclosure 21 Mar, 10:52 AM SMS Pharmaceuticals - Quaterly Results 8 Feb, 7:04 PM SMS Pharmaceuticals - Quaterly Results 8 Feb, 7:04 PM SMS pharmaceuticals informs about closure of trading window 29 Dec, 12:03 PM SMS Pharmaceuticals informs about disclosure 22 Dec, 12:45 PM Sms Pharmaceuticals informs about disclosure 15 Dec, 4:54 PM Sms Pharmaceuticals informs about disclosure 15 Dec, 3:10 PM SMS Pharmaceuticals informs about disclosure 15 Dec, 2:22 PM SMS Pharmaceuticals informs about transcript of conference call 18 Nov, 3:06 PM SMS Pharmaceuticals informs about disclosure 16 Nov, 10:07 AM SMS Pharmaceuticals informs about disclosure 15 Nov, 2:20 PM

SMS Pharmaceuticals Stock Price Analysis and Quick Research Report. Is SMS Pharmaceuticals an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse SMS Pharmaceuticals. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). SMS Pharmaceuticals has a PE ratio of 29.7701062406945 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. SMS Pharmaceuticals has ROA of 4.9487% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. SMS Pharmaceuticals has a Current ratio of 1.5831.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. SMS Pharmaceuticals has a ROE of 9.5322%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. SMS Pharmaceuticals has a Debt to Equity ratio of 0.517 which means that the company has low proportion of debt in its capital.

  • Sales growth: SMS Pharmaceuticals has reported revenue growth of 35.8608% which is fair in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of SMS Pharmaceuticals for the current financial year is 16.493646789049%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for SMS Pharmaceuticals is Rs 0.4 and the yield is 0.1681%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of SMS Pharmaceuticals is Rs 7.9254. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of SMS Pharmaceuticals in Ticker for free. Also, one can get the intrinsic value of SMS Pharmaceuticals by using Valuation Calculators, which are available with a Finology ONE subscription. 

SMS Pharmaceuticals FAQs

Q1. What is SMS Pharmaceuticals share price today?
Ans: The current share price of SMS Pharmaceuticals is Rs 235.94.

Q2. What is the market capitalisation of SMS Pharmaceuticals?
Ans: SMS Pharmaceuticals has a market capitalisation of Rs 2091.65599582 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of SMS Pharmaceuticals?
Ans: The PE ratio of SMS Pharmaceuticals is 29.7701062406945 and the P/B ratio of SMS Pharmaceuticals is 3.02578340910402, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of SMS Pharmaceuticals share?
Ans: The 52-week high share price of SMS Pharmaceuticals is Rs 398, and the 52-week low share price of SMS Pharmaceuticals is Rs 176.05.

Q5. Does SMS Pharmaceuticals pay dividends?
Ans: Currently, SMS Pharmaceuticals pays dividends. Dividend yield of SMS Pharmaceuticals is around 0.1681%.

Q6. What are the face value and book value of SMS Pharmaceuticals shares?
Ans: The face value of SMS Pharmaceuticals shares is Rs 1, while the book value per share of SMS Pharmaceuticals is around Rs 77.9765. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of SMS Pharmaceuticals?
Ans: SMS Pharmaceuticals has a total debt of Rs 280.1787 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of SMS Pharmaceuticals?
Ans: The ROE of SMS Pharmaceuticals is 9.5322% and ROCE of SMS Pharmaceuticals is 11.253%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is SMS Pharmaceuticals a good buy for the long term?
Ans: The SMS Pharmaceuticals long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is SMS Pharmaceuticals undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the SMS Pharmaceuticals appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check SMS Pharmaceuticals’s financials?
Ans: You can review SMS Pharmaceuticals’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about SMS Pharmaceuticals

SMS Pharmaceuticals Limited Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

SMS Pharmaceuticals Limited is a leading pharmaceutical company based in India. With a strong focus on manufacturing and supplying a wide range of active pharmaceutical ingredients (APIs), intermediates, and formulations, the company has established itself as a trusted player in the industry.

The company boasts a robust manufacturing infrastructure, including multiple state-of-the-art facilities that adhere to strict regulatory guidelines and quality standards. With a strong commitment to research and development, SMS Pharmaceuticals Limited continues to innovate and develop new products to meet the evolving needs of the pharmaceutical market.

SMS Pharmaceuticals Limited - Share Price

The share price of SMS Pharmaceuticals Limited reflects the market value of the company's stocks. Investors keen on long-term stock analysis can closely monitor the share price as an indicator of the company's performance and growth potential.

For a comprehensive analysis of the SMS Pharmaceuticals Limited share price, investors can utilize the pre-built screening tools available on our website. These tools provide valuable insights into various factors that may influence the share price, such as market trends, historical data, and peer comparison.

SMS Pharmaceuticals Limited - Balance Sheet

The balance sheet of SMS Pharmaceuticals Limited gives investors a snapshot of the company's financial position. It reveals information about the company's assets, liabilities, and shareholders' equity. By analyzing the balance sheet, investors can assess the company's financial health and stability.

To perform a detailed balance sheet analysis, investors can make use of our premium features. These features offer tools such as DCF Analysis, BVPS Analysis, Earnings Multiple Approach, and DuPont Analysis. These analytical tools provide a comprehensive understanding of the company's financial performance and help in the calculation of fair value.

SMS Pharmaceuticals Limited - Annual Report

The annual report of SMS Pharmaceuticals Limited is a valuable resource for investors seeking a comprehensive understanding of the company's operations and financial performance over a specific period. It provides a detailed analysis of the company's business strategies, market outlook, achievements, and future prospects.

On our website, investors can access and download the annual reports of SMS Pharmaceuticals Limited. These reports are a key source of information for long-term stock investors looking for in-depth stock analysis and insights into the company's performance.

SMS Pharmaceuticals Limited - Dividend

Dividend payment is an important consideration for long-term stock investors. SMS Pharmaceuticals Limited has a track record of consistent dividend payments, reflecting its financial stability and commitment to rewarding shareholders.

Investors can keep track of the company's dividend history and payout ratio to assess the potential returns on their investment. Our website provides up-to-date information on SMS Pharmaceuticals Limited's dividend payouts, ensuring that investors have access to the latest data.

SMS Pharmaceuticals Limited - Quarterly Result

The quarterly result of SMS Pharmaceuticals Limited provides investors with timely information on the company's financial performance and operational updates. By analyzing the quarterly results, investors can gauge the company's growth trajectory and its ability to meet set targets.

Investors can leverage our pre-built screening tools to access the quarterly results of SMS Pharmaceuticals Limited. These tools provide a comprehensive overview of the company's financial highlights without the inclusion of specific financial data points.

SMS Pharmaceuticals Limited - Stock Price Chart

The stock price chart of SMS Pharmaceuticals Limited presents a visual representation of the company's stock performance over a specific period. It helps investors identify trends, patterns, and potential buying or selling opportunities.

On our website, investors can find an interactive stock price chart for SMS Pharmaceuticals Limited, coupled with various technical indicators. These features enable investors to conduct a thorough analysis of the stock's price movements and make informed investment decisions.

SMS Pharmaceuticals Limited - News

Staying updated with the latest news is crucial for long-term stock investors. Our website provides a dedicated section for SMS Pharmaceuticals Limited news, where investors can access relevant information regarding the company's developments, collaborations, regulatory changes, and market updates.

By regularly checking the news section, investors can stay informed and make well-informed decisions based on the latest market trends and events affecting SMS Pharmaceuticals Limited.

SMS Pharmaceuticals Limited - Concall Transcripts

Concall transcripts play a significant role in understanding the company's business strategies, financial performance, and market outlook. They offer insights into the discussions and presentations made during the company's conference calls with analysts and investors.

On our website, investors can easily access and download the concall transcripts of SMS Pharmaceuticals Limited. These transcripts serve as an additional resource for long-term stock investors seeking a deeper understanding of the company's prospects and performance.

SMS Pharmaceuticals Limited - Investor Presentations

Investor presentations provide an overview of SMS Pharmaceuticals Limited's business overview, growth strategies, financial performance, and future outlook. These presentations are designed to give investors a comprehensive understanding of the company's operations and growth prospects.

At our website, investors can find downloadable investor presentations of SMS Pharmaceuticals Limited. These presentations are a valuable resource for those looking to analyze the company's potential and make well-informed investment decisions.

SMS Pharmaceuticals Limited - Promoters and Shareholders

Promoters and shareholders play a crucial role in the success and governance of SMS Pharmaceuticals Limited. Promoters are individuals or entities who have initiated the company, while shareholders are individuals or entities who hold shares in the company.

Our website provides detailed information about the promoters and major shareholders of SMS Pharmaceuticals Limited. Investors can gain insights into the company's ownership structure and the key individuals or entities driving its growth.

By considering the insights provided on our website and utilizing the pre-built screening tools and premium features, long-term stock investors can conduct a thorough stock analysis of SMS Pharmaceuticals Limited. We aim to empower our users with the necessary resources to make informed investment decisions based on accurate and reliable information. 

SMS Pharmaceuticals + Growing Reserves

SMS Pharmaceuticals + Solid Reserves Growth

SMS Pharmaceuticals has significantly increased its total reserves, rising from Rs 358.96 Cr in March 2020 to Rs 562.02 Cr by March 2024. This impressive growth suggests a strong retention of earnings, providing financial robustness and support for future endeavors.

SMS Pharmaceuticals + Borrowing Trends

The company witnessed a peak in borrowings of Rs 149.50 Cr in March 2022, which slightly moderated to Rs 122.09 Cr by March 2024. These changes in borrowing levels reflect adjustments in the company’s leverage strategy, impacting its capital structure.

SMS Pharmaceuticals + Liability Management

The total liabilities of SMS Pharmaceuticals have continuously grown, reaching Rs 1,083.25 Cr in March 2024. A significant increase in current liabilities from Rs 154.21 Cr in March 2020 to Rs 346.72 Cr in March 2024 suggests a rise in short-term financial obligations.

SMS Pharmaceuticals + Asset and Investment Profile

With total assets matching liabilities at Rs 1,083.25 Cr in March 2024, the asset base expansion is anchored by substantial growth in current assets, from Rs 227.78 Cr in March 2020 to Rs 548.89 Cr by March 2024. This indicates enhanced operational capabilities.

This data presents an analysis for the Standalone Balance Sheet of SMS Pharmaceuticals.

For investors, understanding such financial fundamentals is crucial in navigating the complexities of investing in sectors like pharmaceuticals, which are represented on indexes like the NSE and BSE.

Read More
X